CA Patent

CA2412856A1 — Pharmaceutical composition for the treatment of pulmonary arterial hypertension

Assigned to Actelion Pharmaceuticals Ltd · Expires 2004-05-27 · 22y expired

What this patent protects

The invention relates to pharmaceutical compositions for the treatment of pulmonary arterial hypertension comprising a prostacyclin or a prostacyclin analogue, preferably epoprostenol, and an endothelia receptor antagonist, preferably bosentan. The invention further provides meth…

USPTO Abstract

The invention relates to pharmaceutical compositions for the treatment of pulmonary arterial hypertension comprising a prostacyclin or a prostacyclin analogue, preferably epoprostenol, and an endothelia receptor antagonist, preferably bosentan. The invention further provides methods for treating a subject suffering from pulmonary arterial hypertension using the compositions of the invention. The concomitant administration of prostacyclin or a prostacyclin analogue and an endothelia receptor antagonist not only increases the efficacy compared to administration of each alone but also reduces the side effects associated with prostacyclin or prostacyclin analogues.

Drugs covered by this patent

Patent Metadata

Patent number
CA2412856A1
Jurisdiction
CA
Classification
—
Expires
2004-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.